ATE316077T1 - Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten - Google Patents

Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten

Info

Publication number
ATE316077T1
ATE316077T1 AT03009384T AT03009384T ATE316077T1 AT E316077 T1 ATE316077 T1 AT E316077T1 AT 03009384 T AT03009384 T AT 03009384T AT 03009384 T AT03009384 T AT 03009384T AT E316077 T1 ATE316077 T1 AT E316077T1
Authority
AT
Austria
Prior art keywords
crth2
treatment
acid derivatives
related diseases
derivatives suitable
Prior art date
Application number
AT03009384T
Other languages
German (de)
English (en)
Inventor
Ly Tai Wie
Yuji Koriyama
Takashi Yoshino
Hiroki Sato
Kazuho Tanaka
Hiromi Sugimoto
Yoshihisa Manabe
Kevin Bacon
Klaus Urbahns
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE316077T1 publication Critical patent/ATE316077T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03009384T 2003-04-25 2003-04-25 Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten ATE316077T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2

Publications (1)

Publication Number Publication Date
ATE316077T1 true ATE316077T1 (de) 2006-02-15

Family

ID=32946880

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03009384T ATE316077T1 (de) 2003-04-25 2003-04-25 Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
AT04727274T ATE494279T1 (de) 2003-04-25 2004-04-14 Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04727274T ATE494279T1 (de) 2003-04-25 2004-04-14 Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate

Country Status (32)

Country Link
US (2) US7812160B2 (enExample)
EP (2) EP1471057B1 (enExample)
JP (2) JP4671955B2 (enExample)
KR (1) KR101110491B1 (enExample)
CN (2) CN101914065A (enExample)
AR (1) AR043885A1 (enExample)
AT (2) ATE316077T1 (enExample)
AU (1) AU2004233966B2 (enExample)
BR (1) BRPI0409733A (enExample)
CA (1) CA2523439C (enExample)
CL (1) CL43596B (enExample)
CY (1) CY1111295T1 (enExample)
DE (2) DE60303238T2 (enExample)
DK (2) DK1471057T3 (enExample)
DO (1) DOP2004000875A (enExample)
ES (2) ES2257616T3 (enExample)
GT (1) GT200400079A (enExample)
HN (1) HN2004000129A (enExample)
IL (1) IL171566A (enExample)
MX (1) MXPA05011399A (enExample)
MY (1) MY147984A (enExample)
NO (1) NO20055588L (enExample)
NZ (1) NZ543693A (enExample)
PE (1) PE20050143A1 (enExample)
PL (1) PL1633726T3 (enExample)
PT (2) PT1471057E (enExample)
RU (1) RU2361865C2 (enExample)
SI (1) SI1633726T1 (enExample)
TW (1) TWI353980B (enExample)
UY (1) UY28286A1 (enExample)
WO (1) WO2004096777A1 (enExample)
ZA (1) ZA200508722B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
DK1718649T3 (da) * 2004-01-31 2009-08-24 Actimis Pharmaceuticals Inc Imidazo[1,2-c]pyrimidinyleddikesyrederivater
JP4051398B2 (ja) 2004-03-11 2008-02-20 アクテリオン ファマシューティカルズ リミテッド テトラヒドロピリドインドール誘導体
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
EP1817282B1 (en) 2004-11-23 2011-07-20 AstraZeneca AB Phenoxyacetic acid derivatives useful for treating respiratory diseases
ATE524182T1 (de) 2005-04-21 2011-09-15 Merck Serono Sa 2,3-substituierte pyrazinsulfonamide als crth2- hemmer
WO2006125784A1 (en) 2005-05-24 2006-11-30 Laboratoires Serono S.A. Tricyclic spiro derivatives as crth2 modulators
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP1937632A1 (en) * 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
WO2007143745A2 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
CA2679198C (en) 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8278310B2 (en) * 2007-06-21 2012-10-02 Actimis Pharmaceuticals, Inc. Amine salts of a CRTH2 antagonist
EP2170838A1 (en) * 2007-06-21 2010-04-07 Actimis Pharmaceuticals, Inc., Particulates of a crth2 antagonist
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
KR20100061746A (ko) 2007-09-25 2010-06-08 액티미스 파마수티컬스 인코포레이티드 Ｃｒｔｈ２ 길항제로서의 ２－ｓ－벤질 치환된 피리미딘
EP2205569B1 (en) 2007-09-25 2012-02-29 Actimis Pharmaceuticals, Inc., Alkylthio pyrimidines as crth2 antagonists
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
MX2010014172A (es) 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
JP5586606B2 (ja) * 2008-09-02 2014-09-10 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストとしての同位体富化されたピリミジン−５−イル酢酸誘導体
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
BRPI0923592A2 (pt) * 2008-12-25 2016-01-26 Taisho Pharmaceutical Co Ltd composto
JP2012517405A (ja) 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
WO2010092043A1 (en) 2009-02-12 2010-08-19 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
JP2013512242A (ja) * 2009-11-24 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリミジン−５−イル酢酸誘導体のコリン塩の多形体を調製する方法
MX2012007927A (es) 2010-01-06 2012-08-15 Panmira Pharmaceuticals Llc Antagonistas de dp2 y usos del mismo.
ES2545865T3 (es) 2010-01-27 2015-09-16 Boehringer Ingelheim International Gmbh Compuestos de pirazol como antagonistas de CRTH2
EP2586772A4 (en) 2010-06-23 2013-11-13 Taisho Pharmaceutical Co Ltd isoquinoline
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
JP2013535456A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
KR102090990B1 (ko) 2010-10-20 2020-03-19 에스더블유아이엠씨 엘엘씨 머플러 등급의 스테인리스 강을 포함하는 넓은 범위의 코팅 및 비코팅 기재에의 접착성이 향상된 수계 코팅 시스템
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｒｔｈ２拮抗薬としてのピラゾール化合物
JP5988253B2 (ja) 2011-05-16 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ［４，６−ビス−ジメチルアミノ−２−［４−（４−トリフルオロメチルベンゾイル−アミノ）ベンジル］ピリミジン−５−イル］酢酸の調製方法
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
US20140148470A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
BR9712000A (pt) * 1996-09-06 1999-08-24 Nippon Kayaku Kk Derivados de acetamida sais dos mesmos composi-Æo farmac-utica inibidores de protease de quimase de desgranula-Æo de mastÄcitos ou de libera-Æo de histamina de mastÄcitos e de ativa-Æo de eosinÄfilo ou de libera-Æo de oxig-nio ativo de eosinÄfilo e processo para produzir os dervados de acetamida
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CN1239485C (zh) * 2000-05-22 2006-02-01 里奥制药有限公司 作为IL－1β和TNF－α抑制剂的二苯酮类
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EP2170838A1 (en) 2007-06-21 2010-04-07 Actimis Pharmaceuticals, Inc., Particulates of a crth2 antagonist
US8278310B2 (en) 2007-06-21 2012-10-02 Actimis Pharmaceuticals, Inc. Amine salts of a CRTH2 antagonist

Also Published As

Publication number Publication date
NO20055588D0 (no) 2005-11-25
KR101110491B1 (ko) 2012-01-31
RU2361865C2 (ru) 2009-07-20
CA2523439C (en) 2012-06-19
PT1471057E (pt) 2006-05-31
EP1633726B1 (en) 2011-01-05
US7812160B2 (en) 2010-10-12
DE602004030907D1 (de) 2011-02-17
UY28286A1 (es) 2004-11-30
CA2523439A1 (en) 2004-11-11
DK1471057T3 (da) 2006-05-15
ES2358424T3 (es) 2011-05-10
TWI353980B (en) 2011-12-11
PL1633726T3 (pl) 2011-06-30
AU2004233966A1 (en) 2004-11-11
EP1633726A1 (en) 2006-03-15
DE60303238D1 (de) 2006-04-06
JP4671955B2 (ja) 2011-04-20
SI1633726T1 (sl) 2011-04-29
IL171566A (en) 2011-03-31
ATE494279T1 (de) 2011-01-15
US7960393B2 (en) 2011-06-14
BRPI0409733A (pt) 2006-05-09
ES2257616T3 (es) 2006-08-01
US20100322980A1 (en) 2010-12-23
NZ543693A (en) 2009-05-31
CN101914065A (zh) 2010-12-15
AU2004233966B2 (en) 2010-11-11
RU2005136655A (ru) 2006-06-10
TW200505873A (en) 2005-02-16
DE60303238T2 (de) 2006-09-14
ZA200508722B (en) 2006-12-27
CN1809539A (zh) 2006-07-26
CN1809539B (zh) 2012-05-09
US20070129355A1 (en) 2007-06-07
CL43596B (es) 2005-03-18
NO20055588L (no) 2006-01-24
EP1471057B1 (en) 2006-01-18
CY1111295T1 (el) 2015-08-05
JP5161290B2 (ja) 2013-03-13
EP1471057A1 (en) 2004-10-27
WO2004096777A1 (en) 2004-11-11
AR043885A1 (es) 2005-08-17
MXPA05011399A (es) 2006-05-31
DK1633726T3 (da) 2011-03-28
HN2004000129A (es) 2009-05-14
HK1095320A1 (en) 2007-05-04
MY147984A (en) 2013-02-28
JP2006524645A (ja) 2006-11-02
PT1633726E (pt) 2011-02-22
GT200400079A (es) 2004-11-30
PE20050143A1 (es) 2005-04-01
JP2011068657A (ja) 2011-04-07
KR20060089622A (ko) 2006-08-09
DOP2004000875A (es) 2004-10-31

Similar Documents

Publication Publication Date Title
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE502005007427D1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1471057

Country of ref document: EP